长春氟宁对比烷化剂治疗经重度预处理的转移性乳腺癌:开放标签随机III期试验
该开放标签III期试验纳入既往接受过至少两种化疗方案且对蒽环类、紫杉类、抗代谢药和长春碱类耐药或不耐受的转移性乳腺癌患者,随机接受长春氟宁280 mg/m2每3周或医生选择的烷化剂单药每3周治疗。主要终点总生存期无差异(HR 1.04,P=0.67;中位9.1 vs 9.3个月),但长春氟宁组疾病控制率显著更高(44% vs 35%,P=0.04)。
要点
- 长春氟宁280 mg/m2每3周未改善经重度预处理转移性乳腺癌的总生存期。
- 长春氟宁组疾病控制率显著高于烷化剂组(44% vs 35%,P=0.04)。
- 两组常见3/4级不良事件为中性粒细胞减少和乏力,长春氟宁组发生率更高。
核心结论
- 长春氟宁280 mg/m2每3周作为转移性乳腺癌三线或后线治疗,与医生选择的烷化剂相比未改善总生存期。
- 长春氟宁显示出可接受的安全性,提示280 mg/m2剂量值得进一步评估。
研究设计与样本
- 开放标签随机III期试验,纳入既往接受过至少两种针对转移性乳腺癌的化疗方案且对蒽环类、紫杉类、抗代谢药和长春碱类耐药或不耐受的患者。
- 共594例患者随机分组,长春氟宁组298例,烷化剂组296例。
- 分层因素为体能状态、既往针对转移性乳腺癌的化疗线数、疾病可测量性和研究中心。
- 主要终点为总生存期。
主要发现
- 总生存期无差异(HR 1.04,P=0.67;长春氟宁中位9.1个月 vs 烷化剂9.3个月)。
- 无进展生存期无差异(HR 0.94,P=0.49;中位2.5个月 vs 1.9个月)。
- 总缓解率无差异(6% vs 4%)。
- 疾病控制率长春氟宁组显著更高(44% vs 35%,P=0.04)。
- 最常见任何级别不良事件为血液学、胃肠道疾病和乏力;最常见3/4级不良事件为中性粒细胞减少(19% vs 11%)和乏力(10% vs 4%)。
临床怎么用
- 对于经重度预处理且对蒽环类、紫杉类、抗代谢药和长春碱类耐药或不耐受的转移性乳腺癌患者,长春氟宁280 mg/m2每3周未显示总生存获益,不作为优先推荐。
- 长春氟宁组疾病控制率更高但总生存无改善,临床决策需结合安全性和患者个体情况。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no standard treatment after progression on second-line chemotherapy for metastatic breast cancer (MBC). We compared vinflunine with physician's choice of alkylating agent (AA) for patients with heavily pretreated MBC. PATIENTS AND METHODS: In this open-label phase III trial, patients with MBC were included if they had received at least two prior chemotherapy regimens for MBC and had received anthracycline, taxane, antimetabolite and vinca alkaloid therapy. Patients were no longer candidates for these chemotherapies because of resistance and/or intolerance. Patients were randomised to either vinflunine 280 mg/m2 intravenously every 3 weeks (q3w) or AA monotherapy q3w. Stratification factors were performance status, number of prior chemotherapy lines for MBC, disease measurability and study site. The primary end point was overall survival (OS). RESULTS: A total of 594 patients were randomised (298 to vinflunine, 296 to AA). There was no difference between treatment arms in OS (hazard ratio 1.04, P = 0.67; median 9.1 months for vinflunine versus 9.3 months for AA), progression-free survival (hazard ratio 0.94, P = 0.49; median 2.5 versus 1.9 months, respectively) or overall response rate (6% versus 4%, respectively). However, the disease control rate was significantly higher with vinflunine than AA (44% versus 35%, respectively; P = 0.04). The most common adverse events (any grade) were haematological and gastrointestinal disorders and asthenia in both arms. The most common grade 3/4 adverse events were neutropenia (19% versus 11% with vinflunine versus AA, respectively) and asthenia (10% versus 4%). CONCLUSIONS: Vinflunine 280 mg/m2 q3w did not improve OS compared with the physician's choice of AA as third- or later-line therapy for MBC. Vinflunine demonstrated an acceptable safety profile, suggesting that vinflunine 320 mg/m2 merits evaluation. CLINICALTRIALS.GOV: NCT01091168.
引用
- Cortes J, Perez-Garcia J, Levy C, et al. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2018. PMID: 29481630. doi:10.1093/annonc/mdy051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。